help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eisenbarth, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eisenbarth, G. S.
Related Collections
Right arrow Pediatric Endocrinology
Right arrow Diabetes and Insulin
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 7 2403-2407
Copyright © 2007 by The Endocrine Society

UPDATE

Update in Type 1 Diabetes

George S. Eisenbarth

Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Aurora, Colorado 80045

Address all correspondence and requests for reprints to: George S. Eisenbarth, M.D., Ph.D., Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Mail Stop B140, P.O. Box 6511, Aurora, Colorado 80045-6511. E-mail: george.eisenbarth{at}uchsc.edu.

Context: Type 1 diabetes is a heterogeneous disorder characterized by severe ß-cell loss. The great majority of patients have type 1A or immune-mediated diabetes.

Synthesis: There has been recent progress in defining the genetics, pathogenesis, and natural history of the disease. In addition, there is a major effort to develop immunotherapies to prevent the disorder and to cure the disease with islet transplantation, and there is potential for dramatic improvement in care with introduction of continuous glucose monitoring devices. The discovery of "metabolic memory" underscores the importance of excellent metabolic control. With comprehensive care, major microvascular complications (e.g. blindness and renal failure) are preventable for most patients.

Conclusion: The existence of multiple "competing" technologies to deal with this devastating disorder holds promise of improved outcomes.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. S. Anderson
Update in Endocrine Autoimmunity
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3663 - 3670.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
V. Butty, C. Campbell, D. Mathis, C. Benoist, and the DPT-1 Study Group
Impact of Diabetes Susceptibility Loci on Progression From Pre-Diabetes to Diabetes in At-Risk Individuals of the Diabetes Prevention Trial-Type 1 (DPT-1)
Diabetes, September 1, 2008; 57(9): 2348 - 2359.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Fourlanos, M. D. Varney, B. D. Tait, G. Morahan, M. C. Honeyman, P. G. Colman, and L. C. Harrison
The Rising Incidence of Type 1 Diabetes Is Accounted for by Cases With Lower-Risk Human Leukocyte Antigen Genotypes
Diabetes Care, August 1, 2008; 31(8): 1546 - 1549.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society